IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men
This study has been completed.
Sponsor:
Friends Research Institute, Inc.
Collaborator:
University of California, Los Angeles
Information provided by (Responsible Party):
Friends Research Institute, Inc.
ClinicalTrials.gov Identifier:
NCT00856323
First received: March 3, 2009
Last updated: August 12, 2016
Last verified: August 2016
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This study seeks to decrease methamphetamine use and concomitant high-risk sexual behaviors among methamphetamine-using men who have sex with men (MSM) by combining a biomedical intervention with a behavioral intervention. The behavioral intervention will consist of an 8-week course of contingency management (CM) through which participants will be reinforced for testing negative for methamphetamine metabolites during periodic urine analyses. The biomedical intervention involves a 28-day course of an antiretroviral drug (Truvada) to be administered after an unanticipated HIV risk exposure (i.e., engaging in either receptive or insertive anal sex without a condom with someone who is HIV-positive or of unknown status). In combining these two interventions, this study seeks to evaluate the combined intervention's effects on sexual risk behaviors and methamphetamine use.
| Condition | Intervention | Phase |
|---|---|---|
| Amphetamine-Related Disorders HIV HIV Infections | Drug: Truvada Behavioral: CM | Phase 2 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Biobehavioral Interventions for HIV-negative Methamphetamine-using MSM |
Resource links provided by NLM:
Further study details as provided by Friends Research Institute, Inc.:
Primary Outcome Measures:
- Self-reported Methamphetamine Use in Previous 30 Days. [ Time Frame: 3-months after baseline ]Mean number of days (of the past 30) of methamphetamine use.
Secondary Outcome Measures:
- Description of Incident STI Infections. [ Time Frame: Baseline and 3-months ]Proportional 3-month incidence of syphilis, rectal gonorrhea, pharyngeal gonorrhea, and rectal Chlamydia.
- HIV-related Sexual Risk Behaviors in Previous 30 Days. [ Time Frame: 3-months after baseline ]Self-reported episodes of Unprotected Anal Intercourse in the previous 30 days.
- Post-Exposure Prophylaxis Medication Adherence [ Time Frame: 28-days ]Median medication adherence rate, defined as the proportion of pills taken relative to the number of pills prescribed (i.e., # of pills taken / # of pills prescribed).
| Enrollment: | 53 |
| Study Start Date: | January 2009 |
| Study Completion Date: | December 2010 |
| Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: PEP/CM
Participants are provided contingency management vouchers for methamphetamine abstinence, and can initiate postexposure prophylaxis (Truvada; 1 pill daily for 28 days) after non-occupational exposure to HIV.
|
Drug: Truvada
At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
Other Name: Emtricitabine and tenofovir disoproxil fumarate
Behavioral: CM
Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for methamphetamine metabolites.
Other Name: Contingency Management
|
Detailed Description:
At the baseline, all eligible participants underwent informed consent; completed baseline assessments; received rapid HIV testing; provided specimens for syphilis, gonorrhea and chlamydia testing; and received a medical examination. Those who reported a high-risk sexual or drug exposure episode with an HIV-positive or serostatus-unknown source within the preceding 72 hours immediately initiated postexposure prophylaxis. All other participants received a 4-day ''starter pack'' of Truvada to be initiated only in the case of a future high-risk exposure to HIV. All participants began the voucher-based CM intervention upon study entry. For the initial 8 weeks of study conduct, participants presented to the study site three times weekly for a urine drug screen for methamphetamine metabolites. Participants who provided urine samples that were negative for methamphetamine metabolites earned vouchers, which escalated in value for successive negative urine samples. A participant with a missing sample or a sample positive for methamphetamine metabolites did not earn vouchers. Accrued vouchers were never forfeited and could be redeemed at any time during the study for gift certificates or goods or services that promote healthy, pro-social behaviors; vouchers could not be redeemed for cash.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Individual must identify as a male who has sex with other men (MSM);
- At least 18 years of age;
- HIV negative serostatus on baseline rapid oral HIV antibody test;
- Self-reported methamphetamine use within the previous 72 hours and test positive for methamphetamine metabolites at baseline;
- Self-reported unprotected anal intercourse (either receptive or insertive) with an HIV-positive or status unknown partner within the previous 3 months;
- Self-reports no previous hypersensitivity to any of the components of Truvada (tenofovir disoproxil fumarate or emtricitabine);
- Willing to comply with study requirements (i.e., monitored urine testing three times per week, meet with physician within first week of enrollment, begin medication immediately following an unexpected high-risk sexual exposure, and contact the clinic and meet with physician within 92 hours of unexpected high-risk sexual exposure).
Exclusion Criteria:
- Does not identify as a male who has sex with other men;
- Under 18 years of age;
- HIV positive, by self-report or as indicated by the results on the baseline rapid oral HIV antibody test;
- Self-reports any previous hypersensitivity to any of the components of Truvada;
- Has not used methamphetamine in the previous 72 hours and does not test positive for methamphetamine metabolites;
- Has not had unprotected anal intercourse with an HIV-positive or status unknown partner within the previous 3 months;
- Unwilling to comply with study requirements.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00856323
Please refer to this study by its ClinicalTrials.gov identifier: NCT00856323
Locations
| United States, California | |
| Friends Community Center | |
| Los Angeles, California, United States, 90028 | |
Sponsors and Collaborators
Friends Research Institute, Inc.
University of California, Los Angeles
Investigators
| Principal Investigator: | Cathy J Reback, Ph.D. | Friends Research Institute, Inc. |
| Principal Investigator: | Raphael J Landovitz, M.D. | UCLA Center for Clinical AIDS Research and Education |
| Principal Investigator: | Steve Shoptaw, Ph.D. | UCLA Department of Family Medicine |
More Information
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Friends Research Institute, Inc. |
| ClinicalTrials.gov Identifier: | NCT00856323 History of Changes |
| Other Study ID Numbers: |
702632 |
| Study First Received: | March 3, 2009 |
| Results First Received: | August 27, 2012 |
| Last Updated: | August 12, 2016 |
| Individual Participant Data | |
| Plan to Share IPD: | No |
Keywords provided by Friends Research Institute, Inc.:
|
Methamphetamine HIV Post-exposure prophylaxis HIV seronegativity |
Additional relevant MeSH terms:
|
HIV Infections Amphetamine-Related Disorders Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Tenofovir Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination |
Emtricitabine Methamphetamine Antiviral Agents Anti-Infective Agents Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Retroviral Agents Anti-HIV Agents Central Nervous System Stimulants Physiological Effects of Drugs Sympathomimetics Autonomic Agents Peripheral Nervous System Agents |
ClinicalTrials.gov processed this record on June 23, 2017